Sevabertinib
- Indication
- HER2-mutant non-small cell lung cancer (NSCLC), for patients who have progressed after or are unsuitable for standard therapy
- Manufacturer
- Bayer (拜耳医药)
- Lecheng Status
- Clinical application initiated (April 2026) at Ruijin Hainan Hospital
- Available At
- 上海交通大学医学院附属瑞金医院海南医院
- Regulatory Status
- FDA: Not yet approved; EMA: Not yet approved; NMPA: Not yet approved (accessible via Lecheng pilot policy)
Common Questions
Who is eligible for this treatment?
Patients with confirmed indication and a treating physician referral. International patients need a medical visa (M visa).
How can I access this treatment in Lecheng?
Contact the hospital listed in the quick facts section. International patients can use medical agents or contact the hospital directly.
What is the cost of treatment?
Costs vary by treatment protocol and length of stay. Please contact the hospital for accurate pricing. International insurance may be accepted.
Indication: HER2-mutant non-small cell lung cancer (NSCLC), for patients who have progressed after or are unsuitable for standard therapy
Manufacturer: Bayer (拜耳医药)
Bayer's oral selective tyrosine kinase inhibitor targeting HER2 mutations. Provides a new precision targeted therapy option for HER2-mutant NSCLC patients who face limited treatment options and poor outcomes with conventional chemotherapy. Lung cancer is China's highest-incidence and highest-mortality malignancy.
Sources & Citations
- hainanlecheng.com · accessed 2026-07-03